Supported by world-class markets data from Dow Jones and FactSet, and partnering with Automated Insights, MarketWatch ...

Eli Lilly (NYSE:LLY) has entered into a licensing agreement with Mediar Therapeutics to advance Mediar's drug MTX-463 into ...

Since the start of 2020, Eli Lilly’s (NYSE: LLY) stock price chart has been straight up and to the right, up 494.50% and ...

Eli Lilly (LLY) is in advanced talks to buy cancer-focused biotech Scorpion Therapeutics in a deal worth up to $2.5B, people close to the talks ...

Eli Lilly is expanding its private financing ambitions, partnering with venture capital firm Andreessen Horowitz on a new ...

Eli Lilly in talks to acquire cancer biotech Scorpion Therapeutics for $2.5 billion, with potential milestone payments.

Investors seeking the next obesity-like market opportunity will be closely watching developments related to treatments for ...

As Meta moves away from fact-checking, HEC Paris professor David Restrepo Amariles warns of fake news' risks for businesses, ...

Venture capital firm Andreessen Horowitz said on Friday it was working with Eli Lilly to launch a $500 million venture fund that will be fully funded by the U.S. drugmaker.

The global insulin delivery pen market is poised for remarkable growth, with its valuation projected to increase from USD ...

Seasoned advisory group including RNA, translation and commercialisation luminaries.

Reaching more mUM patients globally with KIMMTRAK (tebentafusp) in 2025 through additional launches and increased community penetrationEnrolling ...